But this comes in second-line breast cancer, a use the group isn’t pursuing.
ApexOnco Front Page
Recent articles
The company admits defeat with zelenectide.
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
Ono's antisense therapy is to begin its first pivotal trial.
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
The company pays $2.5bn for Day One and its approved drug Ojemda.
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
